#Saudi Arabia #Riyadh #Biologics #MS Pharma

MS Pharma Launches MENA's First Biologics Manufacturing Hub

MS Pharma has marked a significant milestone by officially launching the first biologics manufacturing facility in the Middle East, strategically located in Saudi Arabia. This state-of-the-art facility has received approval from the Saudi Food and Drug Authority (SFDA) and is designed to comply with the stringent guidelines set by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

The investment, totaling USD 50 million, positions MS Pharma at the forefront of the biologics market in the region. The facility is equipped with capabilities including formulation, fill-finish, and lyophilization processes. This development not only positions MS Pharma as a key player in biologics but also establishes the facility as a reliable partner for international pharmaceutical companies seeking access to the Saudi market and the broader MENA region through local manufacturing options and contract manufacturing solutions.

Specializing in monoclonal antibodies and complex peptides, which are among the most sought-after categories of biologic treatments worldwide, the new plant also boasts the region's first in-house bioanalytical laboratories. This feature significantly reduces the dependency on overseas testing services, thereby speeding up the time required to bring vital treatments to market.

Ghiath Sukhtian, Chairman of MS Pharma, expressed pride in this launch, stating, "This is a defining moment for both MS Pharma and the MENA biopharmaceutical sector. We are committed to advancing a regional biologics platform that meets global healthcare needs while delivering complex medicinal solutions through collaboration with global partners."

Kalle Känd, CEO of MS Pharma, added, "This facility is more than just a manufacturing site; it is a strategic enabler for global partnerships. By offering localized access and contract manufacturing opportunities, we are unlocking localization incentives that enhance our contribution to national and regional objectives related to local content and high-skilled job creation."

The inauguration aligns seamlessly with Saudi Arabia's Vision 2030 initiative, focusing on localization and industrial growth. It strategically positions the Riyadh facility to serve not only the Kingdom but also the MENA market and export opportunities in Europe and the U.S. This reinforces MS Pharma’s leadership role in biologics and showcases its ability to meet diverse market needs while fostering partnerships.

Founded in 1989 in Amman, Jordan, MS Pharma is dedicated to enhancing access to top-notch medications across the Middle East, Africa, and beyond. Currently employing over 2,000 individuals in 12 countries, it operates five production sites in Jordan, Algeria, and Saudi Arabia. The company's portfolio includes the development, manufacturing, and distribution of generics, complex injectables, and biosimilars aimed at treating various therapeutic areas, ranging from oncology to cardiovascular diseases, contributing to improved health outcomes throughout the region.

In conclusion, the establishment of MS Pharma's biologics facility in Saudi Arabia marks a pivotal step in the evolution of biopharmaceutical manufacturing in the MENA region. This facility not only enhances local production capabilities but also lays the groundwork for future collaborations and advancements in healthcare innovation.